Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel … Read more
Market Cap & Net Worth: Energenesis Biomedical Co. Ltd. (6657)
Energenesis Biomedical Co. Ltd. (TW:6657) has a market capitalization of $127.18 Million (NT$4.21 Billion) as of March 19, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #18298 globally and #827 in its home market, demonstrating a 0.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Energenesis Biomedical Co. Ltd.'s stock price NT$47.95 by its total outstanding shares 87758000 (87.76 Million).
Energenesis Biomedical Co. Ltd. Market Cap History: 2023 to 2026
Energenesis Biomedical Co. Ltd.'s market capitalization history from 2023 to 2026. Data shows change from $160.21 Million to $127.18 Million (-11.23% CAGR).
Energenesis Biomedical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Energenesis Biomedical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.86x
Energenesis Biomedical Co. Ltd.'s market cap is 14.86 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $160.21 Million | $7.16 Million | -$260.38 Million | 22.38x | N/A |
| 2024 | $134.74 Million | $7.75 Million | -$231.08 Million | 17.39x | N/A |
| 2025 | $114.05 Million | $7.67 Million | -$258.40 Million | 14.86x | N/A |
Competitor Companies of 6657 by Market Capitalization
Companies near Energenesis Biomedical Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Energenesis Biomedical Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Energenesis Biomedical Co. Ltd. Historical Marketcap From 2023 to 2026
Between 2023 and today, Energenesis Biomedical Co. Ltd.'s market cap moved from $160.21 Million to $ 127.18 Million, with a yearly change of -11.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$127.18 Million | +11.51% |
| 2025 | NT$114.05 Million | -15.35% |
| 2024 | NT$134.74 Million | -15.89% |
| 2023 | NT$160.21 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Energenesis Biomedical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $127.18 Million USD |
| MoneyControl | $127.18 Million USD |
| MarketWatch | $127.18 Million USD |
| marketcap.company | $127.18 Million USD |
| Reuters | $127.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.